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Alternative splicing changes are frequently observed
in cancer and are starting to be recognized as
important signatures for tumor progression and
therapy. However, their functional impact and rele-
vance to tumorigenesis remain mostly unknown.
We carried out a systematic analysis to characterize
the potential functional consequences of alternative
splicing changes in thousands of tumor samples.
This analysis revealed that a subset of alternative
splicing changes affect protein domain families
that are frequently mutated in tumors and poten-
tially disrupt protein-protein interactions in cancer-
related pathways. Moreover, there was a negative
correlation between the number of these alternative
splicing changes in a sample and the number of
somatic mutations in drivers. We propose that a
subset of the alternative splicing changes observed
in tumors may represent independent oncogenic
processes that could be relevant to explain the func-
tional transformations in cancer, and some of them
could potentially be considered alternative splicing
drivers (AS drivers).
INTRODUCTION
Alternative splicing provides the potential to generate diversity
at RNA and protein levels from an apparently limited number of
loci in the genome (Yang et al., 2016). Besides being a critical
mechanism during development, cell differentiation, and regula-
tion of cell-type-specific functions (Norris and Calarco, 2012),
alternative splicing is also involved in multiple pathologies,
including cancer (Chabot and Shkreta, 2016). Many alternative
splicing changes recapitulate cancer-associated phenotypes
by promoting angiogenesis (Vorlova´ et al., 2011), inducing cell
proliferation (Yanagisawa et al., 2008), or avoiding apoptosis
(Karni et al., 2007). Alternative splicing changes may originateCell Re
This is an open access article undfrom somatic mutations that disrupt splicing regulatory motifs
in exons and introns (Jung et al., 2015; Supek et al., 2014), as
well as through mutations or expression changes in core and
auxiliary splicing factors, which impact the splicing of cancer-
related genes (Bechara et al., 2013; Darman et al., 2015; Madan
et al., 2015; Zong et al., 2014). Alterations in alternative splicing
are also emerging as relevant targets of therapy (Lee and Abdel-
Wahab, 2016). For instance, lung tumors with an exon skipping in
the proto-oncogene MET respond to MET-targeted therapies
despite not having any other activating alteration in this gene
(Frampton et al., 2015; Paik et al., 2015). Alternative splicing is
also important in drug resistance. For example, a proportion
of non-responders to BRAF-targeted therapy express a BRAF
isoform lacking exons 4–8, which encompass the RAS binding
domain (Poulikakos et al., 2011). Similarly, alternative splicing
of CD19 in relation to the aberrant activity of the splicing fac-
tor SRSF3 impairs immunotherapy in leukemia (Sotillo et al.,
2015). Thus, specific alterations in splicing induce functional
impacts that provide a selective advantage to tumor cells and
could represent targets of therapy.
Despite the prevalence of alternative splicing in tumors and its
relation to therapy, tumor progression, and metastasis (Lee and
Abdel-Wahab, 2016; Lu et al., 2015; Trincado et al., 2016), its
functional impacts have not been exhaustively described. Alter-
native splicing changes can confer radical functional changes
(Wang et al., 2005), remodel the network of protein-protein inter-
actions in a tissue-specific manner (Buljan et al., 2012; Ellis et al.,
2012), and expand the protein interaction capabilities of genes
(Yang et al., 2016). Here, we present a systematic evaluation of
the potential functional impacts of alternative splicing changes
in cancer samples. We described splicing changes in terms
of transcript isoforms switches per tumor sample and deter-
mined the protein features and protein-protein interactions they
affected. Our analysis revealed a set of isoform switches that
affectproteindomains fromfamilies frequentlymutated in tumors,
remodel the protein interaction network of cancer drivers, and
tend to occur in patients with low number of mutations in cancer
drivers. Furthermore, a subset of them has driver-like properties
and, hence, could play a role in the neoplastic process indepen-
dently of or in conjunction with mutations in cancer drivers.ports 20, 2215–2226, August 29, 2017 ª 2017 The Author(s). 2215
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
RESULTS
Patient-Specific Definition of Isoform Switches across
Multiple Cancer Types
To determine the potential functional impacts of alternative
splicing in cancer, we analyzed the expression of human tran-
script isoforms in 4,542 samples from 11 cancer types from
The Cancer Genome Atlas (TCGA) (Supplemental Experimental
Procedures). We described splicing changes using transcript
isoforms, as they represent the endpoint of transcription and
splicing, and ultimately determine the functional capacity of
cells. For each gene and each patient sample, we calculated
the differential transcript isoform usage between the tumor and
normal samples. An isoform switch was defined as a pair of
transcripts, the tumor and the normal isoforms, such that the
change in relative abundance in a single patient in both isoforms
was higher than the observed variability across normal samples.
Moreover, the involved gene must not show differential expres-
sion between tumor and normal. Additionally, we discarded
switches with a significant association with stromal or immune
cell content (Supplemental Experimental Procedures). The
final set of switches identified and that we kept for further anal-
ysis had a mean change in relative abundance of 54% and a
SD of 7%.
In all patients, we found a total of 8,122 different isoform
switches in 6,442 genes that described consistent changes in
the transcriptome of the tumor samples and that would not be
observable by simply measuring gene expression changes (Fig-
ure 1A; Table S1). These switches occurred in 4,443 patients:
each switch in 5 or more patients, with the majority (75%) occur-
ring in 10 or more patients (Table S1). Using SUPPA (Alamancos
et al., 2015), we calculated the relation with local alternative
splicing events (Supplemental Experimental Procedures). From
the 8,122 switches, 5,667 (69.7%) were mapped to one or
more local alternative splicing events. Compared with the ex-
pected proportion of event types, we observed an enrichment
of alternative 50ss, alternative first exon and retained intron,
and a depletion of alternative 30ss, alternative last exon, mutually
exclusive exons, and exon cassette (Figure S1A). Mapping the
tumor isoform to either form of the event, we observed that re-
tained intron events are predominantly retained, in agreement
with previous observations (Dvinge and Bradley, 2015), whereas
exon-cassette events were predominantly skipped (Figure S1B).
Interestingly, 30.3% of the switches were not mapped to any
event, indicating that transcripts provide a wider spectrum of
RNA variation compared to local alternative splicing events.
Isoform Switches in Cancer Are Frequently Associated
with Protein Feature Losses
We next studied the proteins encoded by the transcripts
involved in switches. Interestingly, annotated proteins in tumor
isoforms tended to be shorter than proteins in normal isoforms
(Figure S1C). Moreover, whereas for most switches—6,937
(85.41%)—both transcript isoforms coded for protein, the rest
had a significantly higher proportion of cases with only the
normal isoform as protein-coding, 732 (9.01%) versus 231
(2.8%; binomial test p value < 2.2e16, using 0.5 as expected
frequency; Table S1), suggesting that isoform switches in tumors2216 Cell Reports 20, 2215–2226, August 29, 2017are associated with the loss of protein coding capacity. To deter-
mine the potential functional impact of the isoform switches, we
calculated the protein features they affected. Out of the 6,937
switches with both isoforms coding for protein, 5,047 (72.7%)
involved a change in at least one of the following features:
Pfam domains; Prosite patterns; general disordered regions;
and disordered regions with potential to mediate protein-protein
interactions (Figure S1D). Interestingly, there was a significant
enrichment in protein features losses when compared with a
set of 100 sets of simulated switches, controlling for isoform
expression (Figure 1B). This enrichment was observed despite
the fact that, for simulated switches, the normal protein isoform
also tended to be longer than the tumor protein isoform (Fig-
ure S1E). This indicates that isoform switches in cancer are
strongly associated with the loss of protein function capabilities.
We focused on the 6,004 (73.9%) isoform switches that had a
gain or loss in at least one protein feature, which we named
‘‘functional switches,’’ as they were likely to impact gene activity
(Table S1). These functional switches included 729 (8.9%) and
228 (2.8%) cases, for which only the normal or the tumor iso-
form, respectively, coded for a protein with one or more protein
features. Interestingly, cancer drivers were enriched in functional
switches (Fisher’s exact test p value = 2.0e05; odds ratio
[OR] = 1.9; Figure S1F). Among the top switches in cancer
drivers, we identified one in RAC1, which was linked before to
tumor initiation and progression (Zhou et al., 2013) and which
we predicted to gain an extra Ras family domain, and one
in TP53, which we predicted to change to a non-coding isoform
(Figure 1C).
To characterize how functional switches affected protein func-
tion, we calculated the enrichment in gains or losses of specific
domain families with respect to their proportions in a reference
proteome. To ensure that this was attributed to a switch and
not to the co-occurrence of two domains, we requested a mini-
mum of two switches in different genes affecting the domain.
We detected 220 and 41 domain families exclusively lost or
gained, respectively, and 13 that were both gained and lost,
more frequently than expected by chance (Table S2). Domain
families that were significantly lost included those involved in
regulation of protein activity (Figure 1D), suggesting effects on
protein-protein interactions. To further characterize these
functional switches, we calculated the proportion of oncogenes
or tumor suppressors that contained domain families enriched
in gains or losses, compared with the reference proteome.
From the 69 cancer drivers with domains enriched in gains,
58 (84%) corresponded to oncogenes (Fisher’s exact test
p value = 0.0066; OR = 0.4). Although tumor suppressors were
not enriched in domain losses, domain families enriched in gains
occurred more frequently in oncogenes than in tumor suppres-
sors (Wilcoxon test p value = 9e04). These results suggest a
similarity between our functional isoform switches and onco-
genic mechanisms in cancer.
Isoform Switches and Somatic Mutations Affect Similar
Domain Families
We conducted various comparisons using our switches and
cis-occurring mutations from whole-exome sequencing (WES)
and whole-genome sequencing (WGS) data (Supplemental
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Figure 1. Patient-Specific Definition of Isoform Switches across Multiple Cancer Types
(A) Number of isoform switches (y axis) calculated in each tumor type, separated according to whether the switches affected an annotated protein feature
(functional) or not (non-functional) and whether they occurred in cancer gene drivers (driver) or not (non-driver).
(B) Number of different protein feature gains and losses in functional switches for each of the protein features considered, which showed significant enrichment
in losses compared to random switches: Pfam (Fisher’s exact test p value = 4.4e23; odds ratio [OR] = 1.5); Prosite (p value = 1.4e08; OR = 1.3); IUPRED
(p value = 1.1e127; OR = 1.3); and ANCHOR (p value = 7.5e139; OR = 1.5).
(C) Top 20 functional switches in cancer drivers (x axis) according to patient count (y axis). Tumor types are indicated by color: breast carcinoma (BRCA); colon
adenocarcinoma (COAD); head and neck squamous cell carcinoma (HNSC); kidney chromophobe (KICH); kidney renal clear-cell carcinoma (KIRC); kidney
papillary cell carcinoma (KIRP); liver hepatocellular carcinoma (LIHC); lung adenocarcinoma (LUAD); lung squamous cell carcinoma (LUSC); prostate adeno-
carcinoma (PRAD); and thyroid carcinoma (THCA).
(D) Cellular component (red) and molecular function (green) ontologies associated with protein domain families that are significantly lost in functional isoform
switches (binomial test; BH-adjusted p value < 0.05). For each functional category, we give the number of switches in which a domain family from this category is
lost, which is also indicated by the color shade.Experimental Procedures). The frequencies of genes or samples
with functional switches were similar to those with protein-
affecting mutations (PAMs) but smaller than the frequencies for
all mutations from WGS data (Figures S2A and S2B), indicating
a similar prevalence of switches and PAMs, but not for switches
and WGS mutations. Because we calculated switches per pa-
tient, we were able to study how these distributed across
patients (Supplemental Experimental Procedures). The top
cases according to the co-occurrence of WGS somatic muta-tions with switches across patients included a switch in the
cancer driver CUX1, although only in 7 patients (Figures S2C
and S2D), whereas the top cases according to the number of
patients with mutations and switches included TP53 as well as
FAM19A5, DST, and FBLN2, which we already described as
isoform switches before (Sebestye´n et al., 2015; Figures S2E
and S2F). In agreement with the observed low association of mu-
tations and switches (Figure S2G), the number of genes with
PAMs and functional switches tended to be inversely correlatedCell Reports 20, 2215–2226, August 29, 2017 2217
0%
5%
10%
15%
20%
0% 2% 4% 6%
Genes with a functional switch
G
en
es
 w
ith
 a
 P
A
M
Tumor
BRCA
COAD
HNSC
KICH
KIRC
KIRP
LIHC
LUAD
LUSC
PRAD
THCA
A
1
1
1
2
2
3
4
4
5
14
11/30
10/22
5
3
3
3
2
2
Losses
B
oth
G
ains
P53 DNA−binding domain
P53 tetramerisation motif
Xylosyltransferase C terminal
Matrixin
CD20−like family
C2 domain of PTEN tumour−suppressor protein
Class II histocompatibility antigen, beta domain
IPT/TIG domain
TB domain
Calcium−binding EGF domain
Immunoglobulin I−set domain
Fibronectin type III domain
Thrombospondin type 1 domain
Cadherin domain
Ras family
Reprolysin (M12B) family zinc metalloprotease
Core histone H2A/H2B/H3/H4
Neurotransmitter−gated ion−channel ligand binding domain
B
*
**
**
0.0
0.2
0.4
0.6
0.8
+ ++ ++
+
Information
M
 a
nd
 S
 a
gr
ee
m
en
t
Coincidence
Observed
Random (x100)
GO Ontology
cellular component
molecular function
C
COL9A3 (MET)
DAAM1 (TP53)
MKNK2 (TP53)
PRDM1 (TP53)
TERF1 (STAG2)
DNER (TP53)
0%
5%
10%
15%
20% 40% 60%
Mutated samples
S
w
itc
he
d 
sa
m
pl
es Tumor
a
a
a
a
a
BRCA
HNSC
KIRP
LUAD
THCA
D
Figure 2. Comparison of Isoform Switches and Somatic Mutations
(A) For each patient sample, color coded according to the tumor type, we indicate the proportion of all genes with protein-affecting mutations (PAMs) (y axis) and
the proportion of genes with multiple transcript isoforms that presented a functional isoform switch in the same sample (x axis).
(B) Domain families that were significantly lost or gained in functional isoform switches that are also significantly enriched in protein-affectingmutations in tumors.
For each domain class, we indicate the number of different switches in which they occurred. We include here the loss of the P53 DNA-binding and P53 tetra-
merization domains, which only occurred in TP53.
(C) Agreement between protein-affecting mutations and functional switches (y axis) measured in terms of the functional categories of the protein domains they
affected (x axis), using two gene ontologies (GOs) at three different GO Slim levels, from most specific (+++) to least specific (+). Random occurrences (plotted in
light color) were calculated by sampling 100 times the same number of GO terms from the reference proteome as those enriched in domain families affected by
functional switches and in domains families affected by PAMs. Agreement was calculated as the percentage of the union of functional categories from both sets
that were common to both. The error bars correspond to the SD calculated from the 100 random samples.
(D) Pairs formed by a cancer driver (in parentheses) and a functional switch from the same pathway and showed significant mutual exclusion (before multiple test
correction) between PAMs and switches across patients in at least one tumor type—color-coded by tumor type. The y axis indicates the percentage of samples
where the switch occurred, and x axis indicates the percentage of samples where the driver was mutated in the same tumor type.(Figure 2A), suggesting a complementarity between PAMs and
switches affecting protein domains.
We explored this complementarity by checking whether
mutations and switches affected the same molecular mecha-
nisms. First, we calculated domain families enriched in PAMs
and found 76 domain families across 11 tumor types enriched
in mutations (Table S2), which were more frequent in cancer2218 Cell Reports 20, 2215–2226, August 29, 2017drivers compared to non-drivers (Wilcoxon test p value <
2.2e16), in agreement with recent reports (Yang et al., 2015).
Then, we compared the domain families enriched in mutations
with those enriched in gains or losses through switches; we
found an overlap of 15 domain families, which was higher than
expected by chance given the domains affected by the 6,004
functional switches and the 5,307 domain families observed
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in the reference proteome (Fisher’s test p value = 5.6e06; OR =
4.7). From the domain families enriched in mutations, 7 showed
enrichment in losses, 6 showed enrichment in gains, and
2 showed enrichment in both (Figure 2B; Table S2). The
gains included cadherin domains related to switches in CHD8,
CDH26, FAT1, FAT2, and FAT3, whereas the losses included
the calcium-binding epidermal growth factor (EGF) domain,
which is affected by various switches, including one inNOTCH4.
A notable case was the loss of the TP53 DNA-binding domain
and the tetramerization motif. Although it occurred in a single
switch, its recurrence in 123 patients highlights the relevance
of TP53 alternative splicing (Bourdon, 2007).
We questioned whether the similarity was beyond the coin-
cidence of single-domain families and could affectmore generally
the function associated to domains. Hence, we calculated the
enriched Gene Ontology (GO) terms associated to the domains
enriched in mutations and switches separately and then calcu-
lated the overlap between both sets. This overlap was compared
to the overlapobtainedby randomly samplinghundred times from
the reference proteome the same number of GO terms found for
domains inenrichedswitchesormutations.Notably, theobserved
overlap was higher than expected for each GO term and at
different GO slim levels (Figure 2C), and the shared functional cat-
egories included receptor activity and protein binding. A total of
754 (12.5%) functional switches in 634 genes (47 of them in 37
cancer drivers) affected domain families that were also enriched
inmutations, supporting the notion that isoformswitches andmu-
tations may impact similar functions in tumors.
If switches and mutations have similar functional impacts,
we would expect a tendency toward mutual exclusion of some
switches with mutations in cancer drivers. In fact, we identified
292 functional switches that were mutually exclusive with so-
matic PAMs in three or more cancer drivers (Fisher’s test
p value < 0.05; Supplemental Experimental Procedures), and
16 of them showed mutual exclusion with at least one cancer
genedriver from the samepathway (TableS3). These16 switches
included one in COL9A3, which had mutual exclusion with MET
mutations in kidney renal papillary cell carcinoma (KIRP), and
one in PRDM1, which showed mutual exclusion with mutations
in TP53 in lung adenocarcinoma (LUAD) (Figure 2D) as well as
in PTEN In lung squamous cell carcinoma (LUSC) (Figure S2H;
Table S3). Despite the observed mutual exclusion, none of the
cases was significant after multiple test correction, indicatingFigure 3. Potential Impact of Isoform Switches in Protein Interactions
(A) Functional switches were divided according to whether they occurred in tumor
PPIs (y axis) that were gained (green), lost (red), or remained unaffected (gray).
Experimental Procedures). Samples from KIRP and LIHC had no PPI-affecting s
(B) Functional switchesmapped to PPIs were divided according to whether they a
functional switches (y axis) that occurred in cancer drivers (black), in interactors o
PPIs affected by switches in driver interactors were significant except for KIRC,
(C) Network for module 11 (Table S6) with PPIs predicted to be lost (red). Canc
respectively. Other genes are indicated in dark blue or light blue if they had a fun
(D) OncoPrint for the samples that present protein-affecting mutations (PAMs) in d
switches are indicated in red (loss in this case). Other switches with no predicted e
each sample by color (same color code as in previous figures). The second top
(black) or not (gray) or whether no mutation data are available for that sample (w
(E) As in (C) for module 28 (Table S6).
(F) OncoPrint for the switches and drivers from (E). Colors are as in (D).
2220 Cell Reports 20, 2215–2226, August 29, 2017that the described switches may not provide strong signatures
for pan-negative tumors (Saito et al., 2015).
Isoform Switches Affect Protein Interactions with
Cancer Drivers
Many of the frequently lost and gained domain families in
functional switches were involved in protein-binding activities,
indicating a potential impact on protein-protein interactions
(PPIs) in cancer. To study this, we used data from five different
sources to build a consensus PPI network with 8,142 nodes,
each node representing a gene (Figure S3). Then, to determine
the effect of switches on the PPI network, we mapped PPIs
from this network to domain-domain interactions (DDIs). Do-
mains involved in DDIs were mapped to the specific protein
isoforms using their encoded protein sequence. For genes with
switches, we then considered those PPIs that could be mapped
to DDIs involving domains mapped on either the normal or the
tumor isoforms (Figure S4). From the 8,142 genes in the PPI
network, 3,243 had at least one isoform switch, and for 1,688
isoform switches (in 1,355 genes), we were able to map at least
one PPI to a specific DDIwith domains on either the normal or the
tumor isoform. A total of 162 of these switches were located in
123 cancer drivers, with the remaining 1,526 in non-driver genes.
For each isoform switch, using the DDI information, we evalu-
ated whether the change between the normal and tumor iso-
forms would affect a PPI from the network by matching the
domains affected by the switch to the domains mediating the
interaction, controlling for the expression of the isoforms pre-
dicted to be interaction partners. We found that 477 switches
(28.3%) in 423 different genes affected domains that mediated
protein interactions and thus likely impacted such interactions.
Most of these interaction-altering switches (n = 414; 86.8%)
caused the loss of the domain that mediated the interaction,
whereas a minority (n = 64; 13.2%) led to a gain of the interacting
domain. Only a switch in TAF9 led to gains and losses of interac-
tions with different partners, mediated by the loss of a TIFIID
domain and a gain of an AAA domain (Table S4).
Notably, switches in driver genes tended to lose PPIs more
frequently than those in non-drivers (Figure 3A). From the 162
switches in drivers, 41 (25.3%) of them altered at least one inter-
action, either causing loss (33 switches) or gain (8 switches).
Moreover, switches that affected domains from families en-
riched in mutations or that showed frequent mutual exclusionwith Cancer Drivers
-specific drivers (yes) or not (no). For each tumor type, we plot the proportion of
All comparisons except for KIRC and LUAD were significant (Supplemental
witches in drivers.
ffected a PPI (yes) or not (no). For each tumor type, we plotted the proportion of
f drivers (dark gray), or in other genes (light gray). All tests for the enrichment of
LUAD, and LUSC (Supplemental Experimental Procedures).
er drivers are indicated in black or gray if they had a functional switch or not,
ctional switch or not, respectively. We do not show unaffected interactions.
rivers or switches from (C). Mutations are indicated in black, and PPI-affecting
ffect on the PPI are depicted in gray. The top panel indicates the tumor type of
panel indicates whether the sample harbors a PAM in a tumor-specific driver
hite).
with mutational drivers also affected PPIs significantly more
frequently than other functional switches (Chi-square test
p value < 2.2e16 and p value = 6.8e08, respectively; Fig-
ure S5). Looking at genes annotated as direct interactors of
drivers, they tended to affect PPIs more frequently than the
rest of functional switches mapped to PPIs (Figure 3B). Addition-
ally, all functional pathways found enriched in PPI-affecting
switches were related to cancer (adjusted Fisher’s exact test
p value < 0.05 and odds ratio > 2; Table S5), reinforcing the func-
tional relevance of these 477 PPI-affecting isoform switches in
cancer.
Isoform Switches Remodel Protein Interaction
Networks in Cancer
To further characterize the role of switches, we calculated mod-
ules in the PPI network (Blondel et al., 2008) using only interac-
tion edges affected by switches (Supplemental Experimental
Procedures). This produced 179 modules involving 1,405 genes
(Table S6). From these, 52modules included a cancer driver, and
47 of them included also switches that involved two protein-cod-
ing isoforms. We tested for the enrichment of genes belonging to
specific protein complexes (Ruepp et al., 2010), complexes
related to RNA processing and splicing (Akerman et al., 2015),
and cancer-related pathways (Liberzon et al., 2015; Table S6;
Supplemental Experimental Procedures). From the 47 mod-
ules described above, 8 showed enrichment in pathways and
complexes: apoptosis-related pathways (module 109 in Table
S6); ubiquitin-mediated proteolysis pathway (module 26); and
ERBB-signaling pathway (module 169), as well as spliceosomal
(module 11); ribosomal (module 170); SMN (module 28); PA700
(module 58); and TFIID (module 66) complexes (Table S6).
In particular, module 11 was enriched in splicing factors and
RNA-binding proteins and included the cancer drivers SF3B1,
FUS, SYNCRIP, EEF1A1, and YBX1 (Figure 3C; Table S6). The
module contained a switch in RBMX involving the skipping
of two exons and the elimination of an RNA recognition motif
(RRM) that would impact interactions with SF3B1, EEF1A1,
and multiple RNA binding protein (RBP) genes (Figure 3C) and
a switch in TRA2B that yielded a non-coding transcript previ-
ously described (Stoilov et al., 2004) and would eliminate an
interaction with SF3B1 and other splicing factors. We also
found a switch in HNRNPC, TRA2A, NXF1, and RBMS2 that
lost interactions with various serine/arginine-rich (SR)-protein-
coding genes. Consistent with a potential functional impact,
the PPI-affecting switches showed mutual exclusion with the
mutational cancer drivers (Figure 3D). Interestingly, this mod-
ule also contained switches in the Importin genes IPO11 and
IPO13, which affected interactions with ubiquitin-conjugating
enzymes UBE2E1, UBE2E3, and UBE2I and which showed
mutual exclusion across different tumor types (Figure 3D). These
results indicate that the activity of RNA-processing factors may
be altered in cancer through the disruption of their PPIs by alter-
native splicing.
Another interesting case was module 28 (Table S6), with
switches in the regulators of translation, EIF4B, EIF3B, and
EIF4E, which affected interactions with the drivers EIF4G1,
EIF4A2, and PABPC1 (Figure 3E). The switch in EIF4B caused
the skipping of one exon, which we predicted to eliminate anRRM domain and lose interactions with drivers EIF4G1 and
PABPC1. The switch in EIF3B yielded a non-coding transcript
that would losemultiple interactions. Although we did not predict
any PPI change for EIF4E, this switch lost eight predicted
ANCHOR regions (Table S4), suggesting a possible effect on
yet to be described interactions. Besides frequent PAMs,
PABPC1 also presented a functional switch that affected 2
disordered regions but did not affect any of the RRMs. In this
case, we did not predict any change in PPI, and the possible
functional impact remains to be discovered. Moreover, the iden-
tified PPI-affecting switches showed mutual exclusion with
PAMs in EIF4G1 and PABPC1 (Figure 3F). These results sug-
gest that isoform switches may impact translational regulation
in tumors through the alteration of PPIs of the corresponding
regulators.
Isoform Switches as Potential Drivers of Cancer
Our results provide evidence that a subset of the alternative
splicing switches (1) induced a gain or loss of a protein domain
from a family frequently mutated in cancer, (2) affected one or
more PPIs, (3) displayed some mutual exclusion with drivers, or
(4) displayed recurrence across patients. One or more of these
properties were fulfilled by 1,662 functional switches, which we
hypothesized could define potential alternative splicing drivers
(potential AS drivers; Figure 4A; Table S1), with the majority of
them (1,080; 65%) affecting mutated domain families and/or
PPIs (Figure 4B). To test possible driver-like properties in these
switches, we calculated their centrality and distance to muta-
tional drivers in thePPI network,whichare considered asdefining
properties for cancer-relevant genes (Jonsson and Bates, 2006).
Potential AS drivers showed greater centrality (Mann-Whitney
test p value < 2.2e16; Figure S6A) and closer distances to tu-
mor-specific drivers (Fisher’s exact test p value < 2.2e16;
OR = 1.5; Figure S6B) compared to the rest of switches.
The prevalence of these potential AS drivers varied across
samples and tumor types. Considering tumor-specific muta-
tional drivers (Mut drivers) and our set of potential AS drivers,
we labeled each patient as AS driver enriched or Mut driver en-
riched according to whether the proportion of switched potential
AS drivers or mutated Mut drivers was higher, respectively. This
partition of the samples indicated that, although Mut drivers
were predominant in patients for most tumor types, potential
AS drivers were predominant for a considerable number of
patients across several tumor types and particularly for kidney
and prostate tumors (Figure 4C). Additionally, regardless of the
tumor type, patients with many mutations in Mut drivers tended
to show a low number of switched potential AS drivers and vice
versa (Figure 4D). The occurrence of copy number alteration
(CNA) drivers also showed a pattern of anti-correlation with
our potential AS drivers similar to the one we found between
Mut drivers and potential AS drivers (Figure S6C). The patient
distribution patterns of candidate AS drivers compared with
mutational or CNA drivers bear resemblance with the proposed
cancer genome hyperbola between mutations and CNAs (Fig-
ure S6D; Ciriello et al., 2013), which supports the notion that
a subset of isoform changes represents alternative, yet-unex-
plored relevant mechanisms that could provide a complemen-
tary route to induce similar effects as genetic mutations.Cell Reports 20, 2215–2226, August 29, 2017 2221
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Figure 4. Isoform Switches as Potential Drivers of Cancer
(A) Number of functional isoform switches and potential AS drivers detected in each tumor type.
(B) Candidate potential AS drivers grouped according to their properties: disruption of PPIs; significant recurrence across patients (recurrence); gain or loss of a
protein feature that was frequently mutated in tumors (affects M_feature); mutual exclusion; and sharing pathway with cancer drivers (pannegative). Horizontal
bars indicate the number of switches for each property. The vertical bars show those in each of the intersections indicated by connected bullet points (Conway
et al., 2017).
(C) Classification of samples according to the relevance of potential AS drivers or Mut drivers in each tumor type. For each tumor type (x axis), the positive y axis
shows the percentage of samples that had a proportion of switched potential AS drivers higher than the proportion of mutated Mut drivers. The negative y axis
shows the percentage of samples in which the proportion of mutated Mut drivers was higher than the proportion of switched potential AS drivers. Only patients
with mutation and transcriptome data are shown.
(D) Each of the patients from (C) is represented according to the percentage of mutated Mut drivers (y axis) and the percentage of switched potential AS drivers
(x axis).DISCUSSION
We have identified consistent and recurrent transcript isoform
switches that impact the function of affected proteins by adding
or removing protein domains that were frequently mutated in
cancer or by disrupting or gaining PPIs—possibly also altering
the formation of protein complexes—with cancer drivers or in
cancer-related pathways. Moreover, we observed that patients
with some of these isoform switches tended not to harbor muta-2222 Cell Reports 20, 2215–2226, August 29, 2017tions in cancer drivers and the other way around. Recently, an
alternative splicing change in NFE2L2 has been described to
lead to the loss of a protein domain and the interaction with
its negative regulator KEAP1, thereby providing an alternative
mechanism for the activation of an oncogenic pathway (Gold-
stein et al., 2016). Similarly, an isoform change in the gene
ATF2 has been shown to drive melanomagenesis (Claps et al.,
2016). These examples, together with the analyses presented
here, support a model by which functions and pathways often
altered in cancer through somatic mutationsmay be affected in a
similar way by isoform changes in some patients and therefore
contribute to the tumor phenotype. Importantly, these isoform
changes could occur without gene expression changes in the
host gene and thus provide an independent catalog of functional
alterations in cancer.
Functional domains and interactions might not always be
entirely lost through a switch, as normal isoforms generally retain
some expression in tumors. This could be partly due to the
uncertainty in the estimate of transcript abundance from RNA
sequencing or to the heterogeneity in the transcriptomes of
tumor cells. Still, a relatively small change in transcript abun-
dance has been shown to be sufficient to trigger an oncogenic
effect in cells (Anczuko´w et al., 2015; Bechara et al., 2013;
Sebestye´n et al., 2016). Additionally, we observed that a number
of isoform changes defined a switch from a protein-coding
transcript to a non-coding one, possibly undergoing non-
sense-mediated decay, which is a widespread mechanism of
alternative-splicing-mediated gene expression regulation (Han-
sen et al., 2009), and could potentially alter function in a way
similar to other isoform changes between protein-coding iso-
forms. The predicted impact on domains and interactions could
therefore be indicative of alterations on regulatory networks with
variable functional effects.
Our description in terms of transcript isoform switches allowed
us to describe more variations in the transcriptome than using
local alternative splicing events and to determine the protein
features potentially gained or lost through splicing changes.
However, this approach has some potential limitations. Accurate
determination of differential transcript usage in genes with many
isoforms requires high coverage and sufficient samples per con-
dition (Sebestye´n et al., 2015), which we expect was mitigated
by our use of the variability across normal samples to determine
significance. Additionally, because we used annotated transcript
isoforms, we may have missed tumor-specific transcripts not
present in the annotation. We also only recovered a small frac-
tion of the entire set of PPIs taking place in the cell. For instance,
we did not characterize those interactions mediated through
low-complexity regions (Buljan et al., 2012; Ellis et al., 2012);
hence, many more interactions and protein complexes may be
affected in tumors.
The origin of the observed splicing changes remains to be
elucidated. We did not find a general association with somatic
mutations in cis. It is possible that small copy number alter-
ations or indels are responsible for these switches but are still
hard to detect with WES and WGS data, and more targeted
searches or deeper sequencing are necessary. An alternative
explanation is that the majority of the switches described occur
through trans-acting alterations, such as the expression change
in splicing factors (Sebestye´n et al., 2016). For instance, muta-
tions in RBM10 or downregulation of QKI lead to the same
splicing change in NUMB that promotes cell proliferation (Be-
chara et al., 2013; Zong et al., 2014), and the oncogenic switch
in RAC1 (Zhou et al., 2013) is regulated by expression changes
in various splicing factors (Gonc¸alves et al., 2009; Pelisch
et al., 2012), which are controlled by pathways often altered in
tumors (Fu and Ares, 2014). Another possibility is that these
switches describe signatures of non-genetic variability (Brocket al., 2009). The intra-tumor heterogeneity could allow recapitu-
lating similar transcriptome phenotypes, which would determine
the fitness of cells and the progression of tumors independently
of somatic mutations. Because natural selection acts on the
phenotype rather than on the genotype, an interesting hypothe-
sis is that specific transcript isoform expression patterns could
define particular tumor phenotypes that would be closely related
to those determined by somatic mutations in drivers, thereby
defining an advantageous phenotype such that the selective
pressure to develop equivalent adaptations is relaxed. Accord-
ingly, our identified isoform switches could play an important
role in the neoplastic process independently of or in conjunction
with the already characterized genetic alterations.EXPERIMENTAL PROCEDURES
Further details and an outline of resources used in this work can be found in
Supplemental Experimental Procedures.
Calculation of Significant Isoform Switches per Patient
We modeled splicing alterations in a gene as a switch between two transcript
isoforms: one normal and one tumoral. For each transcript, the relative abun-
dance per sample, which we called proportion spliced-in (PSI), was calculated
by normalizing its abundance in transcripts per million (TPM) units by the sum
of abundances of all transcripts in the same gene. Then, for each transcript and
sample, we calculated the change in relative abundance as DPSI = PSItumor 
PSIref, where PSItumor is the relative abundance in the tumor sample and PSIref
is the normal reference value, which is the value of the paired normal sample,
when available, or the median of PSIs in the normal samples for the same tis-
sue type otherwise. We considered significant those changes with jDPSIj >
0.05 andwith empirical p < 0.01 in the comparison of the observed jDPSIj value
with the distribution of jDPSIj values obtained by comparing the normal sam-
ples pairwise without repetition. We only kept those cases for which the tumor
isoform PSI was higher than the normal isoform in the tumor sample and
the normal isoform PSI in the normal sample was higher than the value for
the tumor isoform. Moreover, we discarded genes that either had an outlier
expression in the tumor sample compared to normal tissues—had expression
below the bottom 2.5% or above the 97.5% of the values of normal expres-
sion—or showed differential expression between the tumor and the normal
samples (Wilcoxon test p value < 0.01 using the gene TPM values).
Candidate switches were defined per patient and per gene, and in some
samples, the same gene could have different switches. We discarded those
switches that contradicted a more frequent switch in the same gene and the
same tumor type. Moreover, we discarded any switch that affected a number
of patients below the top 99% of the distribution of patient frequency of these
contradictory switches in each tumor type. Lastly, we filtered out switches
that were significantly lowly recurrent, i.e., they occurred in fewer patients
than expected by chance (binomial test; adjusted p value < 0.05, using all tu-
mor types). As a consequence, none of the reported switches occurred in less
than 5 samples. Thus, a switch in a patient sample was defined as a pair of
transcripts in a gene with no expression change and with significant changes
in opposite directions that showed consistency across a minimum number of
patients. We aggregated the switches from the different tumor types to get the
final list (Table S1).
Simulated Switches
To simulate switches between normal and tumor tissues, we used genes
withmore than one expressed isoform. For each gene, we selected the isoform
with the highest median expression across the normal samples as the normal
isoform and an arbitrary different transcript expressed in the tumor samples
as the tumor isoform. For each gene, we generated a maximum of five such
simulated switches.
Functional Switches
A switch was defined as functional if both isoforms overlapped in genomic
extent and there was a change in the encoded protein, including cases whereCell Reports 20, 2215–2226, August 29, 2017 2223
only one of the isoforms was coding and, moreover, there was a gain or loss of
a protein feature: Pfam domains (Finn et al., 2016) mapped with InterProScan
(Jones et al., 2014); ProSite patterns (Gattiker et al., 2002); disordered regions
from IUPred (Doszta´nyi et al., 2005); and disordered regions potentially
involved in PPIs from ANCHOR (Doszta´nyi et al., 2009). For IUPred and
ANCHOR, we only considered changes involving at least 5 amino acids.
Switches without any mapped protein features were not considered.
Significance on the enrichment of protein features losses versus gains
was calculated by comparing the number of gains and losses in switches
with the same numbers in simulated switches (Supplemental Experimental
Procedures).
Enrichment of Domain Families in Switches and Mutations
To find protein domain families significantly affected by switches, we first calcu-
lated a reference proteome for each tumor type. Using geneswith multiple tran-
scripts, we selected those that had at least one isoformwith TPM> 0.1 and only
kept the isoformwith the highestmedian expression across the normal samples
in the same tissue type. Proteins encoded by these isoforms were considered
the reference proteome in each tumor type. We aggregated the reference pro-
teomes from all tumor types to form a pan-cancer reference proteome. The ex-
pected frequency of a protein feature was then measured as the proportion of
this feature in the reference proteome. This expected frequency was then
used to calculate the probability of a feature to be affected by a switch using
a binomial test with the number of times the feature was gained or lost in
switches and the total number of feature gains or losses due to switches (Sup-
plemental Experimental Procedures). We selected cases with Benjamini-Hoch-
berg (BH)-adjusted p value < 0.05. Additionally, to ensure the specificity of the
enrichment for each domain class, we considered only domain families affected
in at least two switches. To calculate domain families enriched in mutations, we
considered again the reference proteome in each tumor type. The expectedmu-
tation rate of a domain family was considered to be the proportion of the length
of domains in the proteome covered by this domain family. We aggregated all
observed mutations falling within each family and calculated the probability of
the observed mutations using a binomial test using the mutation count for a
domain family and the total mutations in all domain families (Supplemental
Experimental Procedures). After correcting for multiple testing, we kept those
cases with a BH-adjusted p value < 0.05. GO analysis was performed using
DcGO (Fang and Gough, 2013). For the enrichment test, we considered signif-
icant those cases with FDR < 0.01 (hypergeometric test).
Protein Interaction Analysis
We created a consensus PPI network using data from PSICQUIC (del-Toro
et al., 2013), BIOGRID (Chatr-Aryamontri et al., 2015), HumNet (Lee et al.,
2011), STRING (Szklarczyk et al., 2011), and from Rolland et al. (2014). The
consensus network was built with interactions appearing in at least four of
these five sources, yielding a total of 8,142 nodes with 29,991 interactions.
To find PPIs likely altered by isoform switches, we first mapped each PPI in
a gene to a specific DDI, using information on DDIs from iPfam (Finn et al.,
2014), DOMINE (Raghavachari et al., 2008), and 3did (Mosca et al., 2014). Do-
mains involved in DDIs were then mapped to specific protein isoforms. For the
genes with switches, we then considered those PPIs that could be mapped to
DDIs involving domains mapped to either the normal or the tumor isoforms. In
total, 3,242 genes with 4,219 switches mapped to one or more interactions in
the consensus network and 1,688 isoform switches (in 1,355 genes) were
mapped to at least one specific DDI. We defined a PPI as lost if it was mapped
to one ormore DDIs in the isoform expressed in the normal tissue, but not in the
isoform expressed in the tumor sample. If multiple domains mediated the
same interaction, it was considered lost if at least one of these domains was
lost in the switch. We defined a PPI as gained if it was mapped to a DDI only
in the tumor isoform, but not in the normal isoform.
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